University of Pittsburgh Cancer Institute (UPCI)

CCSG Acknowledgement

Required CCSG Acknowledgement

The NCI requires that publications acknowledge the UPCI CCSG support, and they are tracking compliance. If a UPCI CCSG-supported Shared Resource provided data used in your publication, please include the following statement in the acknowledgment section of your publication(s):

"This project used the UPCI [insert name(s) of shared resource(s)] that [is/are] supported in part by award P30CA047904."

Shared Resource Directors: Please make sure to include this statement on all of your order forms, contracts, etc. as a reminder to your users to acknowledge the UPCI CCSG support.


Personalized medicine requires the integration of information from many imaging modalities. UPCI's In Vivo Imaging Facility (IVIF) provides unique state-of-the-art resources, both clinical and preclinical, including simultaneous MR/PET, ultra high-field magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT) and optical (bioluminescence and fluorescence) and ultrasound small animal imaging. These modalities are supported by in-house contrast agent development (MR, optical and PET).

The goals of the facility include:

  1. Facilitating protocol development for cancer detection, diagnosis and staging
  2. Providing methods for clinical assessment of early therapeutic response
  3. Providing preclinical assessment of biomarker expression throughout cancer treatment

Click below to learn more about our services and modalities.

Preclinical Imaging Clinical Imaging